Catheter Precision (VTAK)
XASE:VTAK
Want to see VTAK full AI Analyst Report?
VTAK Stock Chart & Stats
$1.81
-$0.02(-4.26%)
At close: 4:00 PM EST
$1.81
-$0.02(-4.26%)
Day’s Range― - ―
52-Week Range$0.75 - $15.68
Previous CloseN/A
Volume115.56K
Average Volume (3M)309.34K
Market Cap
$2.37M
Enterprise Value$12.50M
Total Cash (Recent Filing)$441.00K
Total Debt (Recent Filing)$11.99M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.79
Shares Outstanding2,692,473
10 Day Avg. Volume759,143
30 Day Avg. Volume309,336
Financial Highlights & Ratios
PEG Ratio-0.83
Price to Book (P/B)280.34
Price to Sales (P/S)2414.57
P/FCF Ratio-237.88
Enterprise Value/Market Cap5.28
Enterprise Value/Revenue11.29
Enterprise Value/Gross Profit24.42
Enterprise Value/Ebitda-0.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-60.8
Revenue Forecast (FY)$10.20M
Bulls Say, Bears Say
Bulls Say
Proprietary ProductOwning a proprietary electrophysiology mapping catheter gives Catheter Precision a structural competitive advantage: unique IP and differentiated clinical capability can drive adoption, create procedural stickiness via disposables, and support pricing power as physicians and hospitals standardize on the device.
Per-Procedure Revenue ModelA per-procedure, single-use product creates a durable recurring revenue stream tied to procedure volumes. If clinical adoption grows, recurring disposable sales scale with utilization, improving unit economics and allowing operating leverage as fixed costs are spread over more procedures.
Strong Revenue Growth TrendVery high recent revenue growth indicates early commercial traction and product-market fit in a nascent base. Sustained multi-period growth would validate the sales channel and support future margin improvement as scale reduces per-procedure overhead and enhances commercialization efficiency.
Bears Say
Severe Cash BurnPersistent negative operating and free cash flow creates ongoing financing risk and constrains the company’s ability to invest in commercialization and R&D. Continued cash burn increases dependency on external capital, which can dilute shareholders or limit strategic options over months.
Deep Negative ProfitabilityExtremely large negative margins show the cost base far exceeds current revenue, reflecting structural imbalance. Without substantial revenue scaling or cost restructuring, losses are likely to persist and impede sustainable pathway to profitability, pressuring long-term capital efficiency.
Capital-Structure Dilution & Strategic Pivot RiskMultiple convertible preferred issuances and the acquisition of aviation assets signal heavy reliance on structured equity financing and a strategic shift away from core devices. This raises dilution risk and distracts management from scaling the medical product business, complicating execution and investor alignment long-term.
Catheter Precision News
VTAK FAQ
What was Catheter Precision’s price range in the past 12 months?
Catheter Precision lowest stock price was $0.75 and its highest was $15.68 in the past 12 months.
What is Catheter Precision’s market cap?
Catheter Precision’s market cap is $2.37M.
When is Catheter Precision’s upcoming earnings report date?
Catheter Precision’s upcoming earnings report date is Aug 17, 2026 which is in 76 days.
How were Catheter Precision’s earnings last quarter?
Currently, no data Available
Is Catheter Precision overvalued?
According to Wall Street analysts Catheter Precision’s price is currently Overvalued.
Does Catheter Precision pay dividends?
Catheter Precision does not currently pay dividends.
What is Catheter Precision’s EPS estimate?
Catheter Precision’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Catheter Precision have?
Catheter Precision has 2,692,473 shares outstanding.
What happened to Catheter Precision’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Catheter Precision?
Currently, no hedge funds are holding shares in VTAK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Catheter Precision
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
Technical Analysis
Ownership Overview
0.52%
Insiders
0.30% Mutual Funds
<0.01% Other Institutional Investors
99.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---